Despite a significant influx of capital commitments into Nigeria’s pharmaceutical sector, the country’s dream of self-sufficiency remains elusive. A recent industry report highlights a stark paradox: while investor interest is at an all-time high—buoyed by over $4.8 billion in potential investments recorded in 2024 alone—local manufacturing capabilities are lagging dangerously behind national targets. The Nigerian government, through the Presidential Initiative on Unlocking the Healthcare Value Chain (PVAC), set an ambitious goal to domesticate 70% of pharmaceutical production by 2030. However, the 2025 Joint Annual Review (JAR) reveals that local production of medicines and health commodities currently sits at a mere 38%.
Most critically, the report indicates zero local production of long-lasting insecticidal nets—a shocking statistic for a country with one of the world’s highest malaria burdens. Furthermore, there has been no increase in the domestic manufacturing of priority tracer medicines, leaving the nation heavily reliant on imports for essential drugs. The disconnect between policy intent and ground reality is driven by persistent structural bottlenecks. Lanre Shittu, Chairman of HMA Medicals Limited, describes the operating environment as hostile, citing exorbitant energy costs and a lack of gas infrastructure as primary cripplers of production. “The infrastructure for gas is not there… we still have a very high-cost operating environment,” Shittu noted, adding that access to credit remains a “dead” end for many manufacturers despite government promises of loan intervention funds.
Francis Meshioye, President of the Manufacturers Association of Nigeria (MAN), echoed these concerns, pointing to the paralyzing effect of high operational costs and poor infrastructure. While recent executive orders waiving duties on raw materials have saved companies millions, stakeholders like Shittu argue these measures must be institutionalized through legislation to survive political transitions. Meanwhile, Anyanwu Okechukwu, Group Managing Director of DCL Laboratories, flagged regulatory inefficiencies, specifically the misclassification of medical equipment by port officials, which continues to disrupt critical supply chains.
The sluggish pace of local pharmaceutical manufacturing has profound economic consequences for Nigeria. With local production stuck at 38%, the country is forced to spend billions of dollars annually importing finished drugs and basic health commodities. This reliance exerts immense pressure on the naira and depletes foreign exchange reserves that could otherwise be directed toward capital infrastructure. Furthermore, the inability to produce goods like malaria nets locally effectively exports jobs to countries like China and India. A robust pharma manufacturing sector is a high-value employer; its stagnation represents a significant loss of skilled employment opportunities for chemists, engineers, and factory workers. Finally, as long as Nigeria relies on imports for over 60% of its medical needs, its healthcare security remains pegged to global supply chains, leaving the national health system exposed to severe shocks and price volatility during global disruptions.
